Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

Table 8 Characteristics of studies included based on treatment regiments standard NACT + anti-VEGF antibody

	Affiliation	Type of study	Stage of disease	Median age	Nº of BRCA1/2 mutated TNBC patients	pCR	Neoadjuvant treatment
Hahnen 2017 Gepar Sixto [49]	Germany	Phase II RCT	II-III	48	26	17	Cb-P-Dox-Beva
Fasching 2018 Gepar Quinto [21]	Germany	Phase III RCT	I-III	48	39	23	E-C + D-Beva

pCR Pathological complete response, Cb Carboplatin, Dox Doxorubicin, C Cyclophosphamide, P Paclitaxel, D Docetaxel, E Epirubicin, Beva Bevacizumab

ISSN: 1897-4287